Rationale for Clinical Practice Guidance

Assessment for Anaemia of CKD (Guidelines 1.1 – 1.5)

Screening for Anaemia

Haemoglobin Level

Kidney Function

Erythropoietin Measurement

Baseline Investigations

Treatment of Anaemia of CKD with Iron (Guidelines 2.1 – 2.7)

Iron Repletion

Initiation of ESA/HIF-PHI and Iron Status

Route of Administration

Upper Limit for Iron Therapy

Treatment of Iron Deficiency without Anaemia

Administration of IV Iron – Safety Recommendations

Monitoring of Treatment – Iron Therapy

Treatment of Anaemia with Erythropoiesis Stimulating Agents (Guidelines 3.1 – 3.7)

Investigations Before Initiating ESA Therapy

Initiation of ESA and Iron Status

Erythropoiesis Stimulating Agents

Treatment of Anaemia with/without ESA therapy – Target Haemoglobin Range

Choice of ESA

Initial ESA Dose

Route of Administration

Frequency of Administration

ESA Dose Adjustments/Specific Situations

Caution in Prescribing ESA in Certain People with CKD

Haemoglobin during ESA Therapy

Resistance to ESA Therapy

Evaluation for ESA Induced Pure Red Cell Aplasia

Hypertension during ESA Therapy

Treatment of Anaemia with HIF-PHI Agents (Guidelines 4.1 – 4.9)

HIF-PHI Agents

HIF-PHI Therapy – Target Haemoglobin

HIF-PHI Dose and Frequency

Prescribing HIF-PHI in Sub-Groups of People with CKD

Safety and Monitoring Response of HIF-PHI

Rationale for Treatment with HIF-PHI Agents

Treatment of Anaemia of CKD with Blood Transfusions (Guidelines 5.1 – 5.1.3)

Blood Transfusion in People with Anaemia of CKD

Management of Peri-Transplant and Post-Transplant Anaemia (Guidelines 6.1 – 6.3.3)

Peri-Transplant Anaemia & Blood Transfusion

Post-Transplant Anaemia

Special Populations (Guidelines 7.1 – 7.3)

Malignancy, Haematological Disease & Pregnancy